Loading...
Header Logo
Keywords
Last Name
Institution

Sukyung Woo

TitleProf,Asoc
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentPharmaceutical Sciences
Address1110 N Stonewall Ave
Oklahoma City OK 73117-1223
Phone405/271-6593
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Chungnam National University, KoreaMS2001Biological Pharmacy
    State University of New York, Buffalo, NYPhD2007Pharmaceutical Sciences
    Center for Cancer Research, NCI/NIH, Bethesda, MDPostdoc2010Clinical Pharmacology

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Sharma A, Benbrook DM, Woo S. Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. PLoS One. 2018; 13(4):e0194046. PMID: 29634717.
      View in: PubMed
    2. Jaiprasart P, Yeung BZ, Lu Z, Wientjes MG, Cui M, Hsieh CM, Woo S, Au JL. Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release. 2018 Jan 28; 270:101-113. PMID: 29203416.
      View in: PubMed
    3. Wang J, Yeung BZ, Cui M, Peer CJ, Lu Z, Figg WD, Guillaume Wientjes M, Woo S, Au JL. Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology. J Control Release. 2017 Dec 28; 268:147-158. PMID: 29054369.
      View in: PubMed
    4. Thapa P, Li M, Karki R, Bio M, Rajaputra P, Nkepang G, Woo S, You Y. Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells. ACS Omega. 2017 Oct 31; 2(10):6349-6360. PMID: 29104951.
      View in: PubMed
    5. Li M, Thapa P, Rajaputra P, Bio M, Peer CJ, Figg WD, You Y, Woo S. Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. J Pharmacokinet Pharmacodyn. 2017 Dec; 44(6):521-536. PMID: 28913666.
      View in: PubMed
    6. Sharma A, Thavathiru E, Benbrook DM, Woo S. Bioanalytical method development and validation of HPLCUV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study. J Pharm Technol Drug Res. 2017; 6. PMID: 29708233.
      View in: PubMed
    7. Morita Y, Kamal M, Kang SA, Zhang R, Lokesh GL, Thiviyanathan V, Hasan N, Woo S, Zhao D, Leslie M, Suh S, Razaq W, Rui H, Gorenstein DG, Volk DE, Tanaka T. E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases. Mol Ther Nucleic Acids. 2016 Dec 13; 5(12):e399. PMID: 27959340.
      View in: PubMed
    8. Thapa P, Li M, Bio M, Rajaputra P, Nkepang G, Sun Y, Woo S, You Y. Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy. J Med Chem. 2016 Apr 14; 59(7):3204-14. PMID: 26974508.
      View in: PubMed
    9. Rajaputra P, Bio M, Nkepang G, Thapa P, Woo S, You Y. Anticancer drug released from near IR-activated prodrug overcomes spatiotemporal limits of singlet oxygen. Bioorg Med Chem. 2016 Apr 01; 24(7):1540-9. PMID: 26928287.
      View in: PubMed
    10. Morita Y, Kamal M, Kang SA, Zhang R, Lokesh GL, Thiviyanathan V, Hasan N, Woo S, Zhao D, Leslie M, Suh S, Razaq W, Rui H, Gorenstein DG, Volk DE, Tanaka T. E-selectin Targeting PEGylated-thioaptamer Prevents Breast Cancer Metastases. Mol Ther Nucleic Acids. 2016; 5:e399. PMID: 28131283.
      View in: PubMed
    11. Devapatla B, Sharma A, Woo S. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer. PLoS One. 2015; 10(9):e0139237. PMID: 26414070; PMCID: PMC4587670.
    12. Sharan S, Woo S. Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities. Front Pharmacol. 2015; 6:33. PMID: 25750626; PMCID: PMC4335258.
    13. Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res. 2012 Apr 01; 18(7):2099-107. PMID: 22307138.
      View in: PubMed
    14. Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD. Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br J Clin Pharmacol. 2011 Aug; 72(2):294-305. PMID: 21392074; PMCID: PMC3162659.
    15. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Apr 20; 28(12):2070-6. PMID: 20308663; PMCID: PMC2860408.
    Woo's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _